IMHOTEP, PJP, and more

OncoPharm by OncoPharmPod

May 14, 202600:09:59Science & Medicine

This week's pod has lots of updates! IMHOTEP: Pre-operative doses of pembrolizumab lead to significant pCR rates in dMMR colon cancer. Real world rates of PJP suggest room for improvement in prophylaxis, especially those...

Related Episodes

Continue listening to more episodes from OncoPharm.

Paradigm and Daraxonrasib in NSCLC

Sep 3, 2026 - 00:14:31

PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs....

Daraxonrasib, Zanidatamab, and CNS Lymphoma Updates

Aug 27, 2026 - 00:20:26

This week's pod has everything: 1. DDI information and dosing for daraxonrasib, now FDA approved and comm...

Iberdomide

Aug 20, 2026 - 00:15:37

CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: Download the Oncology Learning C...

Kidney Cancer in a Nutshell

Aug 13, 2026 - 00:16:12

Overview of renal cell carcinoma Learning Oncology Companion:

Small Cell Lung Cancer and CINV Updates

Aug 6, 2026 - 00:17:35

This week's episode covers some updates in small cell lung cancer, chemotherapy-induced nausea/vomiting (...

Zidesamtinib & PPIs in Pacific

Jul 30, 2026 - 00:16:32

A new drug is approved for ROS1 NSCLC after a prior TKI (with some data in patients after 2 TKIs). Zidesa...

Gedatolisib et al

Jul 23, 2026 - 00:18:16

This week's pod covers some brief updates comparing the timelines of the FDA approvals for daraxonrasib v...

Endurance Part 2

Jul 16, 2026 - 00:15:12

Did lenalidomide maintenance in multiple myeloma just get limited to 2 years? Endurance Trial, Part 2: Le...